In Vitro Measurement and In Vivo Prediction of Combination Safety of Rivaroxaban with Tyrosine Kinase Inhibitors: A Medication Safety Assessment Study
Tingting Zhaoa,b #, Xuening Lia, b, #, Yanwei Chenc, #, Dalong Wanga, Liyan Wangc, Shan Zhaod, Changyuan Wanga, b, Qiang Menga, b, Huijun Suna, b, Kexin Liua, b, Jingjing Wua, b*
aDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
bProvincial Key Laboratory for Pharmacokinetics and Transport, Liaoning Dalian Medical University, Dalian, Liaoning, China.
cDepartment of Pharmacy, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
dDalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
# These authors contributed equally to this work.
* Correspondence:
Dr. Jingjing Wu
ORCID: 0000-0002-5046-9996
Department of Clinical Pharmacology, College of pharmacy
Dalian Medical University
9 West Section, Lvshun South Road, Lvshunkou District, Dalian 116044, China